Global Oncolytic Virus Therapy Market Size study, by Type (Oncolytic Wild Type Viruses, Genetically Engineered Oncolytic Viruses), by Application (Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer) and Regional Forecasts 2018-2025
Global Oncolytic Virus Therapy Market to reach USD XX million by 2025.
Global Oncolytic Virus Therapy Market valued approximately USD XX million in 2017 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2018-2025. The Oncolytic Virus Therapy Market is continuously growing across the world over the coming years. The major driving factor of global oncolytic virus therapy market are rising adoption of diagnostic & therapeutics procedure and increase in the number of patients with cancers. The major restraining factor of global oncolytic virus therapy market are lack of awareness among users and new class of anticancer immunotherapy. Oncolytic virus therapy is a virus that preferentially infects and kills cancer cells are destroyed by oncolysis, they extract new infectious viral particles to destroy the remaining tumor. The oncolytic viruses conduct the twice functions as they are not causing only the destruction of cancer infected cells but also stimulate the host anti-tumor immune response & don’t allow the expansion of tumor cells.
The regional analysis of Global Oncolytic Virus Therapy Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to well-developed healthcare infrastructure with massive investment in R&D of oncolytic virus immunotherapy. Europe also contributes a satisfactory growth in the global oncolytic Virus therapy market. Asia-Pacific is also anticipated to exhibit higher growth rate / CAGR over the forecast period 2018-2025 due to increased government initiatives.
The major market player included in this report are:
By Type:
Global Oncolytic Virus Therapy Market valued approximately USD XX million in 2017 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2018-2025. The Oncolytic Virus Therapy Market is continuously growing across the world over the coming years. The major driving factor of global oncolytic virus therapy market are rising adoption of diagnostic & therapeutics procedure and increase in the number of patients with cancers. The major restraining factor of global oncolytic virus therapy market are lack of awareness among users and new class of anticancer immunotherapy. Oncolytic virus therapy is a virus that preferentially infects and kills cancer cells are destroyed by oncolysis, they extract new infectious viral particles to destroy the remaining tumor. The oncolytic viruses conduct the twice functions as they are not causing only the destruction of cancer infected cells but also stimulate the host anti-tumor immune response & don’t allow the expansion of tumor cells.
The regional analysis of Global Oncolytic Virus Therapy Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to well-developed healthcare infrastructure with massive investment in R&D of oncolytic virus immunotherapy. Europe also contributes a satisfactory growth in the global oncolytic Virus therapy market. Asia-Pacific is also anticipated to exhibit higher growth rate / CAGR over the forecast period 2018-2025 due to increased government initiatives.
The major market player included in this report are:
- Biovex
- Cell Genesys
- Crusade Laboratories
- Genelux Corporation
- Lokon Pharma
- Merck
- MultiVir
By Type:
- Oncolytic Wild Type Viruses
- Genetically Engineered Oncolytic Viruses
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Melanoma
- Brain Tumor
- Blood Cancer
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia Pacific
- China
- India
- Japan
- Latin America
- Brazil
- Mexico
- Rest of the World
- Historical year – 2015, 2016
- Base year – 2017
- Forecast period – 2018 to 2025
- Key Consulting Companies & Advisors
- Large, medium-sized, and small enterprises
- Venture capitalists
- Value-Added Resellers (VARs)
- Third-party knowledge providers
- Investment bankers
- Investors
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Key Trends
1.3. Global & Segmental Market Estimates & Forecasts, 2015-2025 (USD Billion)
1.3.1. Oncolytic Virus Therapy Market, by Type, 2015-2025 (USD Billion)
1.3.2. Oncolytic Virus Therapy Market, by Application, 2015-2025 (USD Billion)
1.3.3. Oncolytic Virus Therapy Market, by Region, 2015-2025 (USD Billion)
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. ONCOLYTIC VIRUS THERAPY MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. ONCOLYTIC VIRUS THERAPY MARKET DYNAMICS
3.1. See Saw Analysis
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
CHAPTER 4. ONCOLYTIC VIRUS THERAPY MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.2. PEST Analysis
4.2.1. Political Scenario
4.2.2. Economic Scenario
4.2.3. Social Scenario
4.2.4. Technological Scenario
4.3. Value Chain Analysis
4.3.1. Supplier
4.3.2. Manufacturers/Service Provider
4.3.3. Distributors
4.3.4. End-Users
4.4. Key Buying Criteria
4.5. Regulatory Framework
4.6. Cost Structure Analysis
4.6.1. Raw Material Cost Analysis
4.6.2. Manufacturing Cost Analysis
4.6.3. Labour Cost Analysis
4.7. Investment Vs Adoption Scenario
4.8. Analyst Recommendation & Conclusion
CHAPTER 5. ONCOLYTIC VIRUS THERAPY MARKET, BY TYPE
5.1. Market Snapshot
5.2. Market Performance - Potential Model
5.3. Key Market Players
5.4. Oncolytic Virus Therapy Market, Sub Segment Analysis
5.4.1. Oncolytic Wild Type Viruses
5.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
5.4.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
5.4.2. Genetically Engineered Oncolytic Viruses
5.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
5.4.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
CHAPTER 6. ONCOLYTIC VIRUS THERAPY MARKET, BY APPLICATION
6.1. Market Snapshot
6.2. Market Performance - Potential Model
6.3. Key Market Players
6.4. Oncolytic Virus Therapy Market, Sub Segment Analysis
6.4.1. Breast Cancer
6.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.4.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.4.2. Lung Cancer
6.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.4.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.4.3. Prostate Cancer
6.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.4.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.4.4. Melanoma
6.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.4.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.4.5. Brain Tumor
6.4.5.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.4.5.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.4.6. Blood Cancer
6.4.6.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.4.6.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
CHAPTER 7. ONCOLYTIC VIRUS THERAPY MARKET, BY REGIONAL ANALYSIS
7.1. Oncolytic Virus Therapy Market, Regional Market Snapshot (2015-2025)
7.2. North America Oncolytic Virus Therapy Market Snapshot
7.2.1. U.S.
7.2.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.2.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.2.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.2.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.2.2. Canada
7.2.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.2.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.2.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.2.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3. Europe Oncolytic Virus Therapy Market Snapshot
7.3.1. U.K.
7.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.3.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.2. Germany
7.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.3.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.3. France
7.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.3.3.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.3.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.3.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.4. Rest of Europe
7.3.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.3.4.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.4.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.4.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4. Asia Oncolytic Virus Therapy Market Snapshot
7.4.1. China
7.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.4.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.2. India
7.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.4.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.3. Japan
7.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.4.3.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.3.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.3.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.4. Rest of Asia Pacific
7.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.4.4.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.4.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.4.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.5. Latin America Oncolytic Virus Therapy Market Snapshot
7.5.1. Brazil
7.5.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.5.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.5.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.5.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.5.2. Mexico
7.5.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.5.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.5.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.5.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.6. Rest of The World
7.6.1. South America
7.6.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.6.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.6.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.6.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.6.2. Middle East and Africa
7.6.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.6.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.6.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.6.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
CHAPTER 8. COMPETITIVE INTELLIGENCE
8.1. Company Market Share (Subject to Data Availability)
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Biovex
8.3.1.1. Overview
8.3.1.2. Financial (Subject to Data Availability)
8.3.1.3. Product Summary
8.3.1.4. Recent Developments
8.3.2. Cell Genesys
8.3.3. Crusade Laboratories
8.3.4. Genelux Corporation
8.3.5. Lokon Pharma
8.3.6. Merck
8.3.7. MultiVir
CHAPTER 9. RESEARCH PROCESS
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.1.6. Research Assumption
1.1. Market Snapshot
1.2. Key Trends
1.3. Global & Segmental Market Estimates & Forecasts, 2015-2025 (USD Billion)
1.3.1. Oncolytic Virus Therapy Market, by Type, 2015-2025 (USD Billion)
1.3.2. Oncolytic Virus Therapy Market, by Application, 2015-2025 (USD Billion)
1.3.3. Oncolytic Virus Therapy Market, by Region, 2015-2025 (USD Billion)
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. ONCOLYTIC VIRUS THERAPY MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. ONCOLYTIC VIRUS THERAPY MARKET DYNAMICS
3.1. See Saw Analysis
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
CHAPTER 4. ONCOLYTIC VIRUS THERAPY MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.2. PEST Analysis
4.2.1. Political Scenario
4.2.2. Economic Scenario
4.2.3. Social Scenario
4.2.4. Technological Scenario
4.3. Value Chain Analysis
4.3.1. Supplier
4.3.2. Manufacturers/Service Provider
4.3.3. Distributors
4.3.4. End-Users
4.4. Key Buying Criteria
4.5. Regulatory Framework
4.6. Cost Structure Analysis
4.6.1. Raw Material Cost Analysis
4.6.2. Manufacturing Cost Analysis
4.6.3. Labour Cost Analysis
4.7. Investment Vs Adoption Scenario
4.8. Analyst Recommendation & Conclusion
CHAPTER 5. ONCOLYTIC VIRUS THERAPY MARKET, BY TYPE
5.1. Market Snapshot
5.2. Market Performance - Potential Model
5.3. Key Market Players
5.4. Oncolytic Virus Therapy Market, Sub Segment Analysis
5.4.1. Oncolytic Wild Type Viruses
5.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
5.4.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
5.4.2. Genetically Engineered Oncolytic Viruses
5.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
5.4.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
CHAPTER 6. ONCOLYTIC VIRUS THERAPY MARKET, BY APPLICATION
6.1. Market Snapshot
6.2. Market Performance - Potential Model
6.3. Key Market Players
6.4. Oncolytic Virus Therapy Market, Sub Segment Analysis
6.4.1. Breast Cancer
6.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.4.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.4.2. Lung Cancer
6.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.4.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.4.3. Prostate Cancer
6.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.4.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.4.4. Melanoma
6.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.4.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.4.5. Brain Tumor
6.4.5.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.4.5.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.4.6. Blood Cancer
6.4.6.1. Market estimates & forecasts, 2015-2025 (USD Billion)
6.4.6.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
CHAPTER 7. ONCOLYTIC VIRUS THERAPY MARKET, BY REGIONAL ANALYSIS
7.1. Oncolytic Virus Therapy Market, Regional Market Snapshot (2015-2025)
7.2. North America Oncolytic Virus Therapy Market Snapshot
7.2.1. U.S.
7.2.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.2.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.2.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.2.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.2.2. Canada
7.2.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.2.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.2.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.2.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3. Europe Oncolytic Virus Therapy Market Snapshot
7.3.1. U.K.
7.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.3.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.2. Germany
7.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.3.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.3. France
7.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.3.3.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.3.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.3.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.4. Rest of Europe
7.3.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.3.4.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.4.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3.4.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4. Asia Oncolytic Virus Therapy Market Snapshot
7.4.1. China
7.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.4.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.2. India
7.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.4.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.3. Japan
7.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.4.3.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.3.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.3.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.4. Rest of Asia Pacific
7.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.4.4.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.4.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4.4.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.5. Latin America Oncolytic Virus Therapy Market Snapshot
7.5.1. Brazil
7.5.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.5.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.5.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.5.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.5.2. Mexico
7.5.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.5.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.5.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.5.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.6. Rest of The World
7.6.1. South America
7.6.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.6.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.6.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.6.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.6.2. Middle East and Africa
7.6.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
7.6.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.6.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.6.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
CHAPTER 8. COMPETITIVE INTELLIGENCE
8.1. Company Market Share (Subject to Data Availability)
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Biovex
8.3.1.1. Overview
8.3.1.2. Financial (Subject to Data Availability)
8.3.1.3. Product Summary
8.3.1.4. Recent Developments
8.3.2. Cell Genesys
8.3.3. Crusade Laboratories
8.3.4. Genelux Corporation
8.3.5. Lokon Pharma
8.3.6. Merck
8.3.7. MultiVir
CHAPTER 9. RESEARCH PROCESS
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.1.6. Research Assumption